Bioarray Genetics

Belkins
Bioarray Genetics is a biotech company located in New Haven, Connecticut. We are committed to transforming cancer treatment decisions and outcomes using gene profiling to provide clinically actionable results to clinicians and patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

ERT EXPANDS CLINICAL IMAGING REPORTING CAPABILITIES IN ITS BUSINESS INTELLIGENCE SUITE

ERT | April 16, 2021

news image

ERT, the worldwide pioneer in clinical endpoint data collection, today declared that its demonstrated Business Intelligence suite has extended to incorporate detailing for clinical preliminary imaging, making study data all the more effectively available and noteworthy. The new imaging capabilities give an elevated degree of data that empowers study pioneers to guarantee consummation, and successfully oversee locales, expenses, and profitability. "Imaging studies are complex,...

Read More

PHARMACY MARKET

ASCENTAGE PHARMA ANNOUNCES ITS 9TH ORPHAN DRUG DESIGNATION FROM THE US FDA IN 2020

Ascentage Pharma | January 05, 2021

news image

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignancies, persistent hepatitis B (CHB), and age-related sicknesses, today reported that the US Food and Drug Administration (FDA) has allowed an Orphan Drug Designation (ODD) to the organization's novel Bcl-2 inhibitor, APG-2575, for the therapy of patients with intense myeloid leukemia (AML). This is the fourth ODD allowed to APG-2575 by the US FD...

Read More

NEW AMR ACTION FUND STEPS IN TO SAVE COLLAPSING ANTIBIOTIC PIPELINE WITH PHARMACEUTICAL INDUSTRY INVESTMENT OF US$1 BILLION

AMR Action Fund | July 09, 2020

news image

Today, more than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund, a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The companies have raised so far nearly US$1 billion new funding to support clinical research of innovative new antibiotics that are addressing the most resi...

Read More

PHARMA TECH

FEDS REBUFF PFIZER'S PLEAS TO SPEED UP SUPPLIES OF COVID-19 VACCINE RAW MATERIALS

Pfizer | December 21, 2020

news image

Since the time Pfizer was fixed to partake in the U.S. government's Warp Speed exertion to get COVID-19 antibodies to showcase, the organization has made it very clear it didn't have to take any bureaucratic cash to build up the immunization. In any case, did that refusal of R&D subsidizing add to Pfizer's failure to produce more dosages of its mRNA antibody for the U.S. market? Pfizer could give more than the 100 million portions it guaranteed in it...

Read More

BUSINESS INSIGHTS

ERT | April 16, 2021

news image

ERT EXPANDS CLINICAL IMAGING REPORTING CAPABILITIES IN ITS BUSINESS INTELLIGENCE SUITE

ERT, the worldwide pioneer in clinical endpoint data collection, today declared that its demonstrated Business Intelligence suite has extended to incorporate detailing for clinical preliminary imaging, making study data all the more effectively available and noteworthy. The new imaging capabilities give an elevated degree of data that empowers study pioneers to guarantee consummation, and successfully oversee locales, expenses, and profitability. "Imaging studies are complex,...

Read More

PHARMACY MARKET

Ascentage Pharma | January 05, 2021

news image

ASCENTAGE PHARMA ANNOUNCES ITS 9TH ORPHAN DRUG DESIGNATION FROM THE US FDA IN 2020

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignancies, persistent hepatitis B (CHB), and age-related sicknesses, today reported that the US Food and Drug Administration (FDA) has allowed an Orphan Drug Designation (ODD) to the organization's novel Bcl-2 inhibitor, APG-2575, for the therapy of patients with intense myeloid leukemia (AML). This is the fourth ODD allowed to APG-2575 by the US FD...

Read More

AMR Action Fund | July 09, 2020

news image

NEW AMR ACTION FUND STEPS IN TO SAVE COLLAPSING ANTIBIOTIC PIPELINE WITH PHARMACEUTICAL INDUSTRY INVESTMENT OF US$1 BILLION

Today, more than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund, a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The companies have raised so far nearly US$1 billion new funding to support clinical research of innovative new antibiotics that are addressing the most resi...

Read More

PHARMA TECH

Pfizer | December 21, 2020

news image

FEDS REBUFF PFIZER'S PLEAS TO SPEED UP SUPPLIES OF COVID-19 VACCINE RAW MATERIALS

Since the time Pfizer was fixed to partake in the U.S. government's Warp Speed exertion to get COVID-19 antibodies to showcase, the organization has made it very clear it didn't have to take any bureaucratic cash to build up the immunization. In any case, did that refusal of R&D subsidizing add to Pfizer's failure to produce more dosages of its mRNA antibody for the U.S. market? Pfizer could give more than the 100 million portions it guaranteed in it...

Read More